Citigroup Maintains Buy on Bio-Techne, Lowers Price Target to $70

Benzinga Newsdesk www.benzinga.com Negative 53.4%

Neg 53.4% Neu 0% Pos 0%

Citigroup analyst Patrick Donnelly maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $80 to $70.